Scarica l'app Stockscreener
687.37
1.18%
7.99
Pre-mercato:
670.00
-17.37
-2.53%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$679.38
Aprire:
$680.17
Volume 24 ore:
3.53M
Relative Volume:
1.46
Capitalizzazione di mercato:
$254.15B
Reddito:
$45.20B
Utile/perdita netta:
$6.87B
Rapporto P/E:
37.79
EPS:
18.1888
Flusso di cassa netto:
$6.75B
1 W Prestazione:
+2.10%
1M Prestazione:
+4.34%
6M Prestazione:
+31.03%
1 anno Prestazione:
+23.19%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$671.47
$704.00
Portata 52W:
$435.27
$704.00
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Nome
Thermo Fisher Scientific Inc
Settore
Industria
Telefono
(781) 622-1000
Indirizzo
168 THIRD AVENUE, WALTHAM, MA
Compare TMO vs DHR, NTRA, A, IQV
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
687.37 | 254.15B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
224.24 | 157.64B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
405.92 | 58.51B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
173.01 | 48.78B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
267.85 | 44.09B | 16.63B | 1.39B | 2.12B | 8.0674 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-09-09 | Aggiornamento | UBS | Neutral → Buy |
| 2026-09-03 | Iniziato | CLSA | Outperform |
| 2026-06-26 | Ripresa | Bernstein | Mkt Perform |
| 2026-06-11 | Iniziato | Piper Sandler | Neutral |
| 2026-06-03 | Downgrade | HSBC Securities | Buy → Hold |
| 2026-06-02 | Ripresa | Wolfe Research | Outperform |
| 2026-05-15 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2026-03-27 | Iniziato | DZ Bank | Buy |
| 2025-12-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-12-09 | Iniziato | Goldman | Buy |
| 2025-12-08 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2025-12-02 | Ripresa | Morgan Stanley | Overweight |
| 2025-12-01 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2025-09-11 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-08-19 | Iniziato | William Blair | Outperform |
| 2025-07-24 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-07-11 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2025-07-09 | Downgrade | UBS | Buy → Neutral |
| 2025-01-10 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2024-12-23 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-14 | Iniziato | Redburn Atlantic | Buy |
| 2024-10-01 | Iniziato | Stephens | Overweight |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-03-18 | Ripresa | Citigroup | Neutral |
| 2024-01-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-01-08 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2023-12-18 | Iniziato | HSBC Securities | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-10-26 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-10-25 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-09-06 | Ripresa | Citigroup | Buy |
| 2023-07-19 | Iniziato | Raymond James | Outperform |
| 2023-07-19 | Reiterato | Robert W. Baird | Outperform |
| 2023-07-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2023-04-04 | Reiterato | Barclays | Overweight |
| 2022-12-14 | Iniziato | Deutsche Bank | Buy |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-10-27 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Iniziato | Credit Suisse | Neutral |
| 2022-04-25 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2022-01-26 | Ripresa | Barclays | Overweight |
| 2021-10-20 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-07-16 | Iniziato | The Benchmark Company | Buy |
| 2021-03-18 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Iniziato | Barclays | Overweight |
| 2021-01-08 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-02 | Iniziato | Goldman | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Iniziato | Atlantic Equities | Overweight |
| 2020-09-14 | Iniziato | Morgan Stanley | Overweight |
| 2020-08-20 | Ripresa | JP Morgan | Overweight |
| 2020-07-15 | Aggiornamento | Cleveland Research | Neutral → Buy |
| 2020-07-07 | Reiterato | Needham | Buy |
| 2020-04-23 | Reiterato | Needham | Buy |
| 2020-01-31 | Reiterato | Needham | Buy |
| 2020-01-22 | Iniziato | Credit Suisse | Neutral |
| 2020-01-08 | Iniziato | Wells Fargo | Equal Weight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-07-25 | Reiterato | Needham | Buy |
| 2019-07-16 | Downgrade | Needham | Strong Buy → Buy |
| 2019-05-30 | Iniziato | Wolfe Research | Outperform |
| 2019-05-23 | Reiterato | Needham | Strong Buy |
| 2019-04-22 | Reiterato | Needham | Strong Buy |
| 2019-04-16 | Reiterato | BofA/Merrill | Buy |
Mostra tutto
Thermo Fisher Scientific Inc Borsa (TMO) Ultime notizie
Why Thermo Fisher (TMO) Could Beat Earnings Estimates Again - Zacks Investment Research
Top Wall Street Forecasters Revamp Thermo Fisher Scientific Expectations Ahead Of Q3 Earnings - Benzinga
Thermo Fisher Scientific Inc. stock: results due October 21 ahead of Xetra open - ad-hoc-news.de
Thermo Fisher (TMO) Reports Earnings Tomorrow: What To Expect - Yahoo Finance
Thermo Fisher Scientific Inc. stock falls Monday, underperforms market - MarketWatch
Forge’s Fierce Life Sciences Announces 2026 Fierce Innovation Awards Finalists and Unveils the Fierce Vanguard Gala - GlobeNewswire Inc.
Thermo Fisher Scientific Inc. expected to post earnings of $6.40 a shareEarnings Preview - TradingView
Beat the Market the Zacks Way: Valero Energy, Hagerty, Palantir in Focus - Zacks Investment Research
Clinical Trial Supplies Market Forecasts Growth from $5.7 Billion (2025) to $10.7 Billion by 2033, Profiling Thermo Fisher Scientific, Catalent, Almac Group, UPS Healthcare & 6 Other Key Players - GlobeNewswire Inc.
Thermo Fisher Scientific (TMO) Is Building A Bigger Role In Precision Diagnostics - Yahoo Finance
Thermo Fisher Scientific Introduces the Thermo Scientific™ EMPAD™ - The National Law Review
Thermo Fisher Scientific (TMO) Stock Gets Fair Value Bump After Q2 Driven Analyst Target Increases - Yahoo Finance
Learn Why The Bull Case For Thermo Fisher Scientific Stock Could Change Following Omics Demand Growth - Yahoo Finance
Thermo Fisher Scientific Outperforms on Strong Results and Life Sciences Recovery - Yahoo Finance
Academic and Government Spending Powers Thermo Fisher (TMO) - Yahoo Finance
Thermo Fisher Scientific (TMO) Q3 2026 Preview: EPS Est. $6.40, Reports October 21 - AlphaStreet
If You Invested $1000 in Thermo Fisher Scientific a Decade Ago, This is How Much It'd Be Worth Now - Yahoo Finance
Lobbying Update: $550,000 of THERMO FISHER SCIENTIFIC INC lobbying was just disclosed - Quiver Quantitative
Thermo Fisher Scientific Inc Stock (TMO) Moved Up by 3.21% on Oct 15: What Investors Need To Know - TradingKey
Thermo Fisher Scientific Inc. stock rises Wednesday, outperforms market - MarketWatch
Global Microbiology Testing Market to Grow Rapidly at a CAGR of ~9% by 2034 | DelveInsight - GlobeNewswire Inc.
Thermo Fisher Scientific (TMO) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Thermo Fisher Scientific stock pre-market at EUR 592.70 - ad-hoc-news.de
Biotech and Pharma Rebound Strengthen Thermo’s (TMO) Organic Growth - Yahoo Finance
Thermo Fisher to Report Q3 Earnings: What's in the Cards? - Zacks Investment Research
Thermo Fisher to Report Q3 Earnings: What's in the Cards? - TradingView
Thermo Fisher’s Expanded Drug Lifecycle Role Might Change The Case For Investing In Thermo Fisher Scientific (TMO) - Yahoo Finance
TD Cowen Adjusts Price Target on Thermo Fisher Scientific to $760 From $675 - www.marketscreener.com
All You Need to Know About Thermo Fisher (TMO) Rating Upgrade to Buy - Zacks Investment Research
Thermo Fisher Scientific stock trades at EUR 587.70, volume is 4.1 percent of average - ad-hoc-news.de
Morgan Stanley Adjusts Price Target on Thermo Fisher Scientific to $730 From $650 - marketscreener.com
BofA raises Thermo Fisher target to USD 745 from USD 650 for Thermo Fisher Scientific stock - ad-hoc-news.de
Thermo Fisher Scientific stock pre-market at EUR 587.40 - ad-hoc-news.de
Thermo Fisher Stock Trades at a Premium. Can Its Earnings Keep Up? - Yahoo Finance
Thermo Fisher Scientific Inc Stock 12‑Month Price Target Raised to $682.12, Implies 5% Upside - TradingView
Thermo Fisher Scientific's Q3 2026 Earnings: What to Expect - Barchart.com
Global Decentralized Clinical Trials Market Size, Trends, and Forecast, 2025-2030 | AI, Wearables, and Cloud-Based Platforms Fuel 13.7% CAGR to $18.8 Billion - GlobeNewswire Inc.
Thermo Fisher Scientific Inc. stock falls Thursday, underperforms market - MarketWatch
What Could Thermo Fisher Scientific (TMO) Change With Its New Digital CMC Consortium? - Yahoo Finance
Why Thermo Fisher Scientific (TMO) Is Back In The Spotlight - Yahoo Finance
Thermo Fisher Scientific Inc. (1TMO.MI) stock price, news, quote and history - Yahoo Finance UK
Thermo Fisher Scientific Inc. (1TMO.MI) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is This the Right Time to Add TMO Stock to Your Portfolio? - Zacks Investment Research
Thermo Fisher Scientific Inc. stock falls Tuesday, underperforms market - MarketWatch
JPMorgan Adds AmEx, Thermo Fisher and Liberty Energy to October Overweight Picks - BigGo Finance
Thermo Fisher Scientific stock heads into October 21 results after a 2.27 percent drop - AD HOC NEWS
Thermo Fisher Scientific (TMO): Strong Q3 Guidance and Broadening Demand Support Multi-Year Outlook - Yahoo Finance
Barclays Adjusts Thermo Fisher Scientific Price Target to $750 From $650, Maintains Overweight Rating - marketscreener.com
Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis - GlobeNewswire Inc.
Preparations begin for Quantum BioPharma's planned Phase 2 multiple sclerosis drug trial - Stock Titan
Thermo Fisher Scientific Inc Azioni (TMO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Thermo Fisher Scientific Inc Azioni (TMO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Pettiti Gianluca | Officer |
Aug 31 '26 |
Proposed Sale |
614.38 |
4,133 |
2,539,233 |
0 |
| Pettiti Gianluca | President & COO |
Aug 31 '26 |
Sale |
614.38 |
4,133 |
2,539,233 |
23,216 |
| CASPER MARC N | Chairman & CEO |
Aug 24 '26 |
Sale |
627.05 |
275 |
172,439 |
123,925 |
| CASPER MARC N | Chairman & CEO |
Aug 24 '26 |
Option Exercise |
309.63 |
275 |
85,148 |
124,200 |
| CASPER MARC N | Officer |
Aug 24 '26 |
Proposed Sale |
627.05 |
275 |
172,438 |
0 |
| CASPER MARC N | Chairman & CEO |
Aug 21 '26 |
Sale |
626.92 |
10,000 |
6,269,153 |
123,925 |
| CASPER MARC N | Officer |
Aug 21 '26 |
Proposed Sale |
626.91 |
10,000 |
6,269,123 |
0 |
| CASPER MARC N | Officer |
Aug 20 '26 |
Proposed Sale |
629.27 |
10,000 |
6,292,653 |
0 |
| CASPER MARC N | Chairman & CEO |
Aug 20 '26 |
Option Exercise |
309.63 |
10,000 |
3,096,300 |
133,925 |
| CASPER MARC N | Chairman & CEO |
Aug 20 '26 |
Option Exercise |
309.63 |
10,000 |
3,096,300 |
133,925 |
0.08%
1.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):